Literature DB >> 26112984

Vasodilator stress with adenosine and the gender preponderance for tolerability and manifestation of adverse symptoms: Is there a physiological basis?

Sandip Basu1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26112984     DOI: 10.1007/s12350-015-0215-3

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  5 in total

1.  Pharmacologic stress perfusion imaging with adenosine: role of simultaneous low-level treadmill exercise.

Authors:  Habib Samady; Frans J Th Wackers; Tammy M Joska; Barry L Zaret; Diwakar Jain
Journal:  J Nucl Cardiol       Date:  2002 Mar-Apr       Impact factor: 5.952

2.  Treadmill exercise during adenosine infusion is safe, results in fewer adverse reactions, and improves myocardial perfusion image quality.

Authors:  G S Thomas; N V Prill; H Majmundar; R R Fabrizi; J J Thomas; C Hayashida; S Kothapalli; J L Payne; M M Payne; M I Miyamoto
Journal:  J Nucl Cardiol       Date:  2000 Sep-Oct       Impact factor: 5.952

3.  Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.

Authors:  Manuel D Cerqueira; Patricia Nguyen; Peter Staehr; S Richard Underwood; Ami E Iskandrian
Journal:  JACC Cardiovasc Imaging       Date:  2008-05

4.  Adenosine stress protocols for nuclear cardiology imaging.

Authors:  B Baskot; S Obradovic; S Rafajlovski; B Gligic; V Orozovic; N Ratkovic; A Ristic-Angelkov; R Jung; V Ivanovic; M Bikicki; M Pavlovic
Journal:  Prilozi       Date:  2008-07

5.  The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging.

Authors:  Gregory S Thomas; Randall C Thompson; Michael I Miyamoto; Tze K Ip; Deborah L Rice; Douglas Milikien; Hsiao D Lieu; Vandana S Mathur
Journal:  J Nucl Cardiol       Date:  2009-01-20       Impact factor: 5.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.